Osteoarthritis
Conditions
Interventions
Group B:Placebo, 4 tabs/day, 2 tabs per time and 2 times pre day, None active ingredient
Group A:Nutrilite Joint Health Product, 4 tabs/day, 2 tabs per time and 2 times pre day, Containing Glucosamien sulfate/turmeric/rhizoma drynariae.
Sponsors
Chinese Center for Desease Control and Prevention
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Men and women 18-75 years of age, with preferable 45-75 years of age; 2. Individual sould be judged to be in good general health on the basis of medical history and physical exam; 3. Clinical diagnosis of mild-to moderate osteoarthritis of the knee. 4. Individual must be willing to make no significant changes to their regular diet and exercise regime throughout the duration of the study; 5. Individual understands the procedures and agrees to participate in the study; 6. Individual is able and willing to provide written informed consent.
Exclusion criteria
Exclusion criteria: 1. Participation in another clinical trial within 30 days of enrollment into the study; 2. Known hypersensitivity to study product or any ingredient in study product; 3. Presence of cardiovascular disease and hypertension with inconsistent medication regimen, unstable conditions, and without proper physician's supervision identified from the findings of the interview; 4. Presence of cancer, diabetes mellitus, rheumatic arthritis, severe secondary osteoarthritis (i.e. posttraumatic), severe osteoarthritis (primary), malformation in bone (i.e. scoliosis) or any other chronic health condition identified from the findings of the interview; 5. Maintaining to use the dietary supplements which are benefit to joint; 6. A change in using of dietary supplements within one week of Day 1. Supplements include any vitamins, minerals, and herbal products, including herbal drinks; 7. A change in drug medication history within 4 weeks prior to screening, or unwilling to maintain current drug therapy throughout the course of the study; 8. A change in hormone therapy, including oral contraceptives, within 4 weeks prior to screening (week -4), or unwilling to maintain current hormone therapy/oral contraceptive use throughout the course of the study; 9. Pregnant or lactating women, or women of child-bearing potential unwilling to use a medically approved form of birth control; 10. History or current abuse of drugs or alcohol, or intake > 2 alcoholic beverages per day; 11. Any condition that the Principal Investigator believes may put the subject at undue risk.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire; | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual analog scale (VAS) questionnaire; | — |
Countries
China
Contacts
Public ContactKeji Li
Outcome results
None listed